4 results about "Glucal" patented technology

This invention discloses a method for preparing a highly water-resistant, glue-free, synergistically cross-linked bamboo-based board, comprising the following steps: preparing polyphenol-modified bamboo powder; adding glucuronic acid solution dropwise to the polyphenol-modified bamboo powder, reacting at 50℃~65℃, then adding citric acid solution, and reacting again to obtain cross-linked modified bamboo powder; adjusting the moisture content of the cross-linked modified bamboo powder to 8wt%~12wt%, and pre-pressing it into a blank; covering the upper and lower surfaces of the blank with a release film and a steel plate respectively, then placing it in a flatbed hot press, and performing segmented pressing molding at 155℃~165℃ to obtain the highly water-resistant, glue-free, synergistically cross-linked bamboo-based board. The resulting board requires no traditional adhesives, possesses high mechanical strength, excellent water resistance, and dimensional stability, and the process is mild with green raw materials, making it suitable for the field of green building materials and providing a new approach for the efficient utilization of bamboo resources.

This invention discloses an engineered bacterial strain for producing xylitol using glucose as the sole carbon source, its construction method, and its applications, belonging to the field of genetic engineering. Using *Escherichia coli* as the starting strain, this invention optimizes the metabolic pathway by knocking out the 2-keto-3-deoxy-6-phosphate glucuronide gene (eda), knocking out the 6-phosphoglucuronide dehydratase gene (edd), and weakening the glucose phosphoisomerase gene (pgi), thus concentrating the carbon flow in the pentose phosphate pathway. Furthermore, it optimizes the metabolic pathway by knocking out or overexpressing endogenous genes such as the ribulokinase gene (araB). Subsequently, the synthesis of xylitol from glucose was experimentally tested by expressing a recombinant expression plasmid containing 2-arabinol dehydrogenase, 4-arabinol dehydrogenase, and xylitol dehydrogenase. This invention, through optimized metabolic pathways, efficiently converts glucose to xylitol without the need for glycerol addition, and significantly increases the yields of both the precursor arabinol and the product xylitol, demonstrating promising production prospects.

A method of preparing glucodiamine, comprising contacting glucose with an enzyme oxidation catalyst under conditions suitable for the formation of glucodialdose; contacting glucodialdose with a nitrogen-containing compound under conditions suitable for the formation of glucodioxime; and reducing glucodioxime under conditions suitable for the formation of glucodiamine. A method of preparing glucodiamine, comprising contacting glucodioxime with a dehydration catalyst under conditions suitable for the formation of glucodinitrile; and reducing glucodinitrile under conditions suitable for the formation of glucodiamine. A chemoenzymatic method of producing a bio-based amide platform chemical, comprising: contacting glucose with a biocatalyst under conditions suitable for the formation of glucodialdose; contacting glucodialdose with a base under conditions suitable for the formation of glucodioxime; and contacting glucodioxime with a hydrogenation catalyst in the presence of hydrogen under conditions suitable for formation of glucodiamine.

This invention discloses a novel use of M1 (Leonurus glucuronide, ZYZ-488), the main glucuronide conjugate metabolite of leonurine, in the preparation of drugs for preventing and treating endometrial damage and / or intrauterine adhesions caused by mechanical curettage. M1 promotes endometrial regeneration, remodeling, and restoration of endocrine function by increasing serum prostaglandin E2 (PGE2) and / or leukemia inhibitory factor (LIF) levels, while simultaneously restoring serum estradiol (E2) and / or progesterone (P4) levels to normal physiological ranges. It also significantly increases endometrial thickness, the number and regular arrangement of glands, improves stroma density, and enhances tissue morphology remodeling. This invention overcomes the technical bias that Phase II metabolites are typically considered inactivated forms, as well as the thrombotic risks of existing estrogen drugs (EVs) and the strong irritation and insufficient long-term protection of the parent compound SCM-198. It provides a safe, mild, stable, and suitable oral formulation for long-term use, offering a novel and effective drug option for the prevention and treatment of clinical endometrial damage and intrauterine adhesions.